The introduction of new targeted anti-HER2 therapies, such as lapatinib, pertuzumab and trastuzumab emtansine (T-DM1), the last one administered with no requirement for simultaneous cytostatics, underlines the importance of identifying patients with HER2-positive breast cancer. The gene discussed is ERBB2; the disease is breast cancer.